SLGL - Sol-Gel Technologies Ltd

81.645
2.645   3.240%

Share volume: 64,017
Last Updated: 03-06-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.14%

PREVIOUS CLOSE
CHG
CHG%
$79.00
2.64
0.03%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
21%
Profitability 25%
Dept financing 9%
Liquidity 43%
Performance 15%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-7.64%
1 Month
25.09%
3 Months
103.48%
6 Months
214.90%
1 Year
13,738.14%
2 Year
7,362.30%
Key data
Stock price
$81.64
P/E Ratio 
0.00
DAY RANGE
$73.50 - $85.50
EPS 
-$1.44
52 WEEK RANGE
$0.40 - $97.97
52 WEEK CHANGE
$13,738.14
MARKET CAP 
19.470 M
YIELD 
N/A
SHARES OUTSTANDING 
27.858 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
04-29-2025
BETA 
2.82
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$30,182
AVERAGE 30 VOLUME 
$29,021
Company detail
CEO: Alon Seri-Levy
Region: US
Website: sol-gel.com
Employees: 50
IPO year: 2018
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Sol-Gel Technologies Ltd. focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system. Twyneo, a novel, once-daily, non-antibiotic topical cream which has completed Phase III clinical trials for the treatment of acne vulgaris, Epsolay, SGT-210, and Erlotinib, Tapinarof, and roflumilast are the company's lead product candidates.

Recent news